Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

Abstract Importance Although sodium‒glucose cotransporter-2 (SGLT2) inhibitors have cardiorenal benefits, their efficacy in patients with type 2 diabetes mellitus (T2DM) and chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) remains underexplored. Objective To evalua...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zinan Zhao, Naixin Zheng, Tianqi Zhang, Chi Zhang, Yuwei Li, Ming Lan, Ni Zhang, Hui Li, Hu Ai, Deping Liu
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Series:	Cardiovascular Diabetology
Subjects:	Dapagliflozin SGLT2 inhibitors Cardiorenal protection Type 2 diabetes mellitus Chronic coronary syndrome Percutaneous coronary intervention
Online Access:	https://doi.org/10.1186/s12933-025-02678-9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

DRESS syndrome with the use of dapagliflozin: A case report and review of literature
by: Rebecca Badawi, et al.
Published: (2025-07-01)

Efficacy and safety of empagliflozin in patients over 65 with type 2 diabetes mellitus complicating cardiorenal syndromes type II and IV
by: Cao Mugen, et al.
Published: (2025-01-01)

Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index
by: Xuehua Liu, et al.
Published: (2025-04-01)

Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes
by: A. O. Bohun
Published: (2024-04-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice
by: M. B. Antsiferov, et al.
Published: (2023-08-01)

Research progress on coronary slow flow or no-reflow of coronary heart disease undergoing percutaneous coronary intervention surgery
by: Mengdi Wang, et al.
Published: (2025-01-01)

IMMEDIATE RESULTS OF DELAYED PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: S. D. Chevgun, et al.
Published: (2017-12-01)

Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention
by: Azhi ShaMa, MM, et al.
Published: (2024-12-01)

Epidemiological Profile of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome in a Single Tertiary Center in Basrah, Iraq
by: Ola Murtadaa Albattat, et al.
Published: (2025-06-01)

Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
by: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
Published: (2025-06-01)

Management of Coronary Vulnerable Plaques: A Focus on Preventive Percutaneous Coronary Intervention
by: Stefano Rigattieri, et al.
Published: (2025-04-01)

Comparing percutaneous coronary intervention and coronary artery bypass grafting for left main stenosis on the basis of current regional registry evidenceCentral MessagePerspective
by: Hristo Kirov, MD, et al.
Published: (2024-12-01)

Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorder
by: Haneen Amawi, et al.
Published: (2025-08-01)

Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2025-02-01)

Cardiorenal syndrome in patients with chronic heart failure
by: L. A. Kovalevskaya, et al.
Published: (2015-08-01)

Percutaneous Coronary Interventions: what the general practitioner should know
by: J.M. Bennett
Published: (2005-02-01)

BIVALIRUDIN AND PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH ACUTE CORONARY SYNDROME: THEORY AND PRACTICE
by: O. V. Averkov
Published: (2012-06-01)

The Effect of Intravascular Imaging-Guided Percutaneous Coronary Intervention on Coronary Artery Perforation
by: Yuichi Sawayama, MD, et al.
Published: (2025-01-01)

Critical endpoints in dynamic follow-up of anemia patients with percutaneous coronary intervention for acute coronary syndrome
by: Margarita A. Simonyan, et al.
Published: (2023-12-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With 3‐Vessel Coronary Artery Disease and Diabetes
by: Ryaan EL‐Andari, et al.
Published: (2025-06-01)

ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS
by: V. A. Sulimov
Published: (2016-01-01)

Characteristics of patients with coronary artery disease and type 2 diabetes mellitus undergoing elective percutaneous coronary intervention
by: Anastasiya G. Neeshpapa, et al.
Published: (2025-01-01)

Effect of Percutaneous Coronary Intervention on Quality of Life among Coronary Artery Disease Patients in Erbil City
by: Chnarb Salahaddin Qadir, et al.
Published: (2025-05-01)

Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA‐SRV Trial
by: Mathieu Albertini, et al.
Published: (2025-06-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

Preoperative hemoglobin predicts clinical outcomes after percutaneous coronary intervention
by: Hailang Liu, et al.
Published: (2025-04-01)

Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness
by: Adarsh Raja, et al.
Published: (2024-12-01)

Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome
by: Wenbo Dai, et al.
Published: (2025-07-01)

Comorbidities and Percutaneous Coronary Intervention in Elderly Patients with Acute Coronary Syndrome
by: M. Yu. Gilyarov, et al.
Published: (2021-05-01)

Effect of rosuvastatin 20 mg pretreatment before percutaneous coronary intervention in patients with acute coronary syndrome
by: Sungho Jo, et al.
Published: (2025-05-01)

Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention
by: Yukinori Harada, et al.
Published: (2016-12-01)

Immediate and short-term outcomes of percutaneous coronary intervention in patients with stable and multivessel coronary artery disease, intolerant to coronary artery bypass grafting
by: Sh. Sh. Zaynobidinov, et al.
Published: (2025-05-01)

Prognostic value of global coronary flow reserve before and after elective percutaneous coronary intervention in patients with chronic coronary syndrome
by: Kai Nogami, et al.
Published: (2024-01-01)

Effectiveness of Nursing Interventions on Patient's Knowledge Undergoing Percutaneous Coronary Intervention
by: Haider Jassim, et al.
Published: (2015-04-01)

Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention
by: Qian Wang, et al.
Published: (2024-12-01)

Long-term outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention without standard modifiable cardiovascular risk factors: findings from the OPT-CAD cohort
by: Zaixin Jiang, et al.
Published: (2025-02-01)

Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data
by: I. S. Egorova, et al.
Published: (2023-01-01)